Global Leading Market Research Publisher QYResearch announces the release of its latest report “Mood Improving Supplement – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Mood Improving Supplement market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Mood Improving Supplement was estimated to be worth US4,200millionin2025andisprojectedtoreachUS4,200millionin2025andisprojectedtoreachUS7,800 million by 2032, growing at a CAGR of 9.2% from 2026 to 2032. For health-conscious consumers, mental wellness seekers, and nutraceutical brand managers, the core business imperative lies in utilizing mood improving supplements that address the critical need for natural, non-prescription alternatives to pharmaceutical antidepressants (SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin-norepinephrine reuptake inhibitors)) and anxiolytics (benzodiazepines, buspirone) for managing stress, anxiety, low mood, depression, irritability, seasonal affective disorder (SAD), perimenopausal mood swings, and sleep disturbances—with fewer side effects (no sexual dysfunction, weight gain, insomnia, gastrointestinal distress, dependence, withdrawal syndrome) and without prescription requirements. Key active ingredients: Ashwagandha (Withania somnifera, root extract, KSM-66, Sensoril, Shoden) — adaptogen reduces cortisol (stress hormone), lowers anxiety (GABAergic (gamma-aminobutyric acid) activity), improves stress resilience, sleep quality, and mental focus; L-theanine (amino acid from green tea, Suntheanine) — promotes relaxation without drowsiness, increases alpha brain waves, reduces stress, improves sleep quality, enhances cognitive performance; Fish Oil (omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid)) — supports serotonin and dopamine pathways, reduces inflammation, improves mood (meta-analyses confirm benefit for depressive symptoms); Others (Saffron (affron) — comparable to fluoxetine (Prozac) for mild-to-moderate depression in RCTs; Rhodiola Rosea — reduces burnout, fatigue, improves mental performance; 5-HTP (5-hydroxytryptophan) — serotonin precursor; St. John’s Wort — mild-to-moderate depression (drug interactions warning); SAMe (S-adenosylmethionine) — neurotransmitter synthesis; Magnesium, Vitamin D, B-complex, Probiotics (psychobiotics)). Applications: online sales (Amazon, iHerb, brand DTC, subscription, social commerce) and offline sales (specialty health stores (GNC, Vitamin Shoppe), pharmacies (CVS, Walgreens, Boots), supermarkets (Whole Foods, Sprouts, Kroger), big-box (Costco, Walmart)). Key suppliers: Makers Nutrition (US – contract manufacturer), Holland & Barrett (UK – retailer, private label), TWINLEAF (US – supplements), DR EMIL NUTRITION, Ashwagandha (brand?), Global Healing (US), West-Coast Pharmaceutical Works Ltd (India), Healthspan (UK), Pure Essentials Supplements, The Nue Co (US – functional wellness), Thorne (US – practitioner channel), Solgar (US – heritage brand), Pharma Nord (Denmark). The market is driven by rising mental health awareness (post-COVID stress and anxiety epidemic), consumer preference for natural over pharmaceutical options, social media influence (TikTok “ashwagandha trend”), and scientific validation.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/releases/5975753/mood-improving-supplement
The Mood Improving Supplement market is segmented as below:
Makers Nutrition
Holland & Barrett
TWINLEAF
DR EMIL NUTRITION
Ashwagandha
Global Healing
West-Coast Pharmaceutical Works Ltd
Healthspan
Pure Essentials Supplements
The Nue Co
Thorne
Solgar
Pharma Nord
Segment by Type
Fish Oil
Ashwagandha
L-theanine
Others
Segment by Application
Online Sales
Offline Sales
1. Market Drivers: Mental Health Crisis, Natural Alternatives, and Adaptogen Popularity
Several powerful forces are driving the mood improving supplement market:
Global mental health crisis (post-COVID) – WHO (World Health Organization): 280 million depression, 300 million anxiety. Waiting lists for therapy (months), side effects of SSRIs. Self-medication with natural supplements.
Adaptogen and stress management trend – Ashwagandha, Rhodiola, Holy Basil (Tulsi). Social media TikTok (hashtag #ashwagandha 500M+ views). KSM-66 ashwagandha clinical studies (cortisol reduction 25%). Gummy formats increase adherence.
“Food as medicine” and preventative mental health – Consumers prefer to address low mood, mild anxiety before clinical diagnosis. Functional beverages (mood drinks), gummies, capsules, powders.
Recent market data (December 2025): According to Global Info Research analysis, Ashwagandha fastest-growing mood supplement with approximately 35% revenue share (adaptogen, stress). Fish Oil (omega-3) 30% share (long-established, EPA/DHA). L-theanine (relaxation) 20% share. Others 15% share (saffron, rhodiola, 5-HTP, St. John’s Wort, SAMe). Online sales dominates with approximately 60% revenue share (Amazon, iHerb, DTC brands, subscriptions). Offline sales 40% share. North America (US) largest market (45% share). Europe (UK, Germany) 30% share. Asia-Pacific (India, Australia, Japan) 20% share (fastest-growing 12-14% CAGR). Thorne, Solgar, Healthspan, Holland & Barrett, TWINLEAF, The Nue Co, Pharma Nord leaders.
2. Key Ingredients and Mechanisms
| Ingredient | Mechanism | Clinical Evidence | Typical Dose (per day) | Onset of Effect | Side Effects | Share |
|---|---|---|---|---|---|---|
| Ashwagandha | Cortisol reduction, GABA agonist, adaptogen | KSM-66 (300mg BID) reduced stress (POMS), anxiety (HAM-A) | 300-600mg (root extract) | 2-4 weeks | Mild GI, drowsiness | ~35% |
| Fish Oil (EPA/DHA) | Anti-inflammatory, serotonin/dopamine pathway modulation | Meta-analysis (25 RCTs) EPA>60% effective for depression | 1000-2000mg (EPA 500-1000mg) | 4-12 weeks | Fishy burp, bleeding (high doses) | ~30% |
| L-theanine | GABA, serotonin, dopamine increase, alpha brain wave | RCT (200mg) stress reduction (salivary cortisol, heart rate) | 100-400mg | 30-60 minutes | None | ~20% |
Other notable ingredients: Saffron (affron, 30mg, comparable to fluoxetine for mild depression). Rhodiola (300-600mg, burnout, fatigue). 5-HTP (50-100mg, serotonin precursor, nausea side effect). St. John’s Wort (300mg TID, drug interactions (CYP3A4 inducer)). SAMe (400-800mg, expensive). Magnesium (glycinate, threonate) for sleep. Vitamin D deficiency mood.
Exclusive observation (Global Info Research analysis): Mood improving supplement market is fragmented among large contract manufacturers (Makers Nutrition), retailers (Holland & Barrett, Healthspan, Global Healing), and specialized wellness brands (The Nue Co, Thorne, TWINLEAF, DR EMIL NUTRITION, Pure Essentials, West-Coast Pharmaceutical Works). Ashwagandha overwhelmingly popular (TikTok). L-theanine combines with caffeine (focus without jitters). Fish oil sold for mood + heart health + brain health. Online sales growing (60%) due to subscription models (monthly delivery) (The Nue Co, Thorne). Private label (Holland & Barrett, Healthspan) competes on price. Gummy format offered by many.
User case – stress and anxiety (December 2025): 35-year-old professional (US) with work stress, insomnia. Takes KSM-66 Ashwagandha 300mg BID (Thorne, Pure Encapsulations, Life Extension). Reduces cortisol, improves sleep quality, less irritability. Purchased online (Amazon). Retail US$25-40 per 60-ct bottle.
User case – SAD (seasonal affective disorder) (January 2026): UK resident (50yo) with winter blues, low energy. Takes fish oil (EPA 1000mg/DHA 500mg) + Vitamin D3 2000IU (Pharma Nord, Healthspan) daily. Mood improved after 6 weeks. Over-the-counter at Boots, Holland & Barrett.
3. Key Challenges and Technical Difficulties
Drug interactions (St. John’s Wort, 5-HTP, SAMe) – St. John’s Wort interacts with oral contraceptives, warfarin, statins, SSRIs (serotonin syndrome risk). 5-HTP + SSRI risk. Label warnings serious.
Lack of standardization across brands – Ashwagandha root extract (KSM-66, Sensoril, Shoden) different concentrations (withanolides 2.5-10%). L-theanine (Suntheanine vs generic). Fish oil (EPA/DHA ratio). Quality variability.
Regulatory claims restricted (US FDA) – Cannot claim “treats depression,” “cures anxiety.” Allowed “supports mood,” “promotes relaxation,” “helps manage stress.” DSHEA (Dietary Supplement Health and Education Act) compliance.
Technical development (October 2025): The Nue Co (US) launched “Gut Feeling” mood probiotic (Bifidobacterium longum 1714, Lactobacillus helveticus R0052) targeting gut-brain axis (psychobiotic). Retail US$55 per 30-ct.
4. Competitive Landscape
Key players include: Makers Nutrition (US – contract manufacturer for many brands), Holland & Barrett (UK – private label), TWINLEAF (US – DTC), DR EMIL NUTRITION, Ashwagandha (brand? unclear), Global Healing (US – natural health), West-Coast Pharmaceutical Works Ltd (India – manufacturing), Healthspan (UK), Pure Essentials Supplements, The Nue Co (US), Thorne (US), Solgar (US – now part of Nestlé), Pharma Nord (Denmark – evidence-based supplements). Thorne, Solgar, The Nue Co premium price. Holland & Barrett, Healthspan mid-range. Makers Nutrition B2B.
Regional dynamics: North America (Thorne, Solgar, The Nue Co, TWINLEAF, Makers Nutrition, Global Healing) largest market. UK/Europe (Holland & Barrett, Healthspan, Pharma Nord). India (West-Coast). Online sales strongest (Amazon, iHerb).
5. Outlook
Mood improving supplement market will grow at 9.2% CAGR to US$7.8 billion by 2032, driven by mental health crisis, adaptogen popularity, and natural alternatives. Technology trends: gummy format (better compliance), liposomal / nanoparticle delivery (enhanced bioavailability), combination formulas (ashwagandha + L-theanine + saffron), and psychobiotics (gut-brain axis). Online sales growth (12-14% CAGR). Ashwagandha and L-theanine fastest-growing.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
